Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06925243

Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: A Prospective, Multicenter, Open-Label, Randomized Controlled Phase III Study

Sponsor: Zuoyi Jiao

Conditions Adjuvant Chemotherapy Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]) MPR Neoadjuvant Therapy ORR,OS,PFS pCR Rate

Interventions Neoadjuvant apatinib combined with sintilimab and perioperative SOX Neoadjuvant sintilimab combined with perioperative SOX

Updated 2 times since 2025 Last updated: Apr 21, 2025 Started: Apr 15, 2025 Primary completion: Dec 31, 2027 Completion: Dec 31, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Adjuvant Chemotherapy and Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), this trial is actively recruiting participants. The trial is conducted by Zuoyi Jiao and has accumulated 2 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE3
May 2025 — Sep 2025 [monthly]

Recruiting PHASE3

First recorded

Apr 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zuoyi Jiao

Data source: Lanzhou University Second Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lanzhou, China